BACKGROUND: Sexual dysfunction is a known complication of adjuvant therapy for breast cancer and an important determinant of quality of life. However, few studies have explored how treatment and other factors affect sexual functioning in young breast cancer survivors. METHODS: Four hundred sixty-one premenopausal women with stage 0 through III breast cancer were surveyed an average of 1 year after diagnosis as part of a prospective cohort study of women who were aged ≤40 years at diagnosis. Sexual interest and dysfunction were assessed using the Cancer Rehabilitation Evaluation System (CARES). Mean CARES scores were compared and multiple regression models were fit to assess treatment and a range of menopausal and somatic symptoms in relation to sexual functioning. RESULTS: Mean CARES sexual interest and dysfunction scores were both highest (indicating poorer functioning) among women who received chemotherapy and were amenorrheic from treatment. After accounting for menopausal and somatic symptoms, treatment-associated amenorrhea remained associated with decreased interest but was no longer an independent predictor of dysfunction. In the multivariable analysis, independent predictors of dysfunction included vaginal pain symptoms, poorer body image, and fatigue. Sexual interest was associated with vaginal pain symptoms, body image, and weight problems. CONCLUSIONS: Factors associated with decreased sexual functioning in young breast cancer survivors can often be ameliorated. The current findings have implications for premenopausal women with other types of cancer who might be experiencing amenorrhea because of chemotherapy or surgery. Increased awareness and early intervention is essential to help improve sexual functioning and associated quality of life for all young cancer survivors.
BACKGROUND:Sexual dysfunction is a known complication of adjuvant therapy for breast cancer and an important determinant of quality of life. However, few studies have explored how treatment and other factors affect sexual functioning in young breast cancer survivors. METHODS: Four hundred sixty-one premenopausal women with stage 0 through III breast cancer were surveyed an average of 1 year after diagnosis as part of a prospective cohort study of women who were aged ≤40 years at diagnosis. Sexual interest and dysfunction were assessed using the Cancer Rehabilitation Evaluation System (CARES). Mean CARES scores were compared and multiple regression models were fit to assess treatment and a range of menopausal and somatic symptoms in relation to sexual functioning. RESULTS: Mean CARES sexual interest and dysfunction scores were both highest (indicating poorer functioning) among women who received chemotherapy and were amenorrheic from treatment. After accounting for menopausal and somatic symptoms, treatment-associated amenorrhea remained associated with decreased interest but was no longer an independent predictor of dysfunction. In the multivariable analysis, independent predictors of dysfunction included vaginal pain symptoms, poorer body image, and fatigue. Sexual interest was associated with vaginal pain symptoms, body image, and weight problems. CONCLUSIONS: Factors associated with decreased sexual functioning in young breast cancer survivors can often be ameliorated. The current findings have implications for premenopausal women with other types of cancer who might be experiencing amenorrhea because of chemotherapy or surgery. Increased awareness and early intervention is essential to help improve sexual functioning and associated quality of life for all young cancer survivors.
Authors: L B Wenzel; D L Fairclough; M J Brady; D Cella; K M Garrett; B C Kluhsman; L A Crane; A C Marcus Journal: Cancer Date: 1999-11-01 Impact factor: 6.860
Authors: N K Arora; D H Gustafson; R P Hawkins; F McTavish; D F Cella; S Pingree; J H Mendenhall; D M Mahvi Journal: Cancer Date: 2001-09-01 Impact factor: 6.860
Authors: Candyce H Kroenke; Bernard Rosner; Wendy Y Chen; Ichiro Kawachi; Graham A Colditz; Michelle D Holmes Journal: J Clin Oncol Date: 2004-05-15 Impact factor: 44.544
Authors: Patricia A Ganz; Lorna Kwan; Annette L Stanton; Janice L Krupnick; Julia H Rowland; Beth E Meyerowitz; Julienne E Bower; Thomas R Belin Journal: J Natl Cancer Inst Date: 2004-03-03 Impact factor: 13.506
Authors: Susan M Allen; Ann C Shah; Arthur M Nezu; Christine Maguth Nezu; Desirée Ciambrone; Joseph Hogan; Vincent Mor Journal: Cancer Date: 2002-06-15 Impact factor: 6.860
Authors: Leticia Aptecar; Frederic Fiteni; Marta Jarlier; Stephanie Delaine; Violaine Guillerme; William Jacot; Veronique D'Hondt Journal: Breast Cancer Res Treat Date: 2021-01-15 Impact factor: 4.872
Authors: Kathryn J Ruddy; Daniel J Schaid; Ann H Partridge; Nicholas B Larson; Anthony Batzler; Lothar Häberle; Ralf Dittrich; Peter Widschwendter; Visnja Fink; Emanuel Bauer; Judith Schwitulla; Matthias Rübner; Arif B Ekici; Viktoria Aivazova-Fuchs; Elizabeth A Stewart; Matthias W Beckmann; Elizabeth Ginsburg; Liewei Wang; Richard M Weinshilboum; Fergus J Couch; Wolfgang Janni; Brigitte Rack; Celine Vachon; Peter A Fasching Journal: Fertil Steril Date: 2019-07-29 Impact factor: 7.329
Authors: Melanie H Jacobson; Ann C Mertens; Jessica B Spencer; Amita K Manatunga; Penelope P Howards Journal: Fertil Steril Date: 2015-12-01 Impact factor: 7.329